1
Lawrence L Kunz, Richard A Klein, John M Reno, David J Grainger, James C Metcalfe, Peter L Weissberg, Peter G Anderson: Therapeutic inhibitor of vascular smooth muscle cells. NeoRx Corporation, Schwegman Lundberg Woessner & Kluth P A, March 31, 1998: US05733925 (479 worldwide citation)

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a ce ...


2
Lawrence L Kunz, Richard A Klein, John M Reno, David J Grainger, James C Metcalfe, Peter L Weissberg, Peter G Anderson: Therapeutic inhibitor of vascular smooth muscle cells. NoeRx Corporation, Schwegman Lundberg Woessner & Kluth P A, June 13, 2000: US06074659 (263 worldwide citation)

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a ce ...


3
Lawrence L Kunz, Richard A Klein, John M Reno, David J Grainger, James C Metcalfe, Peter L Weissberg, Peter G Anderson: Therapeutic inhibitor of vascular smooth muscle cells. NeoRx Corporation, Schwegman Lundberg Woessner & Kluth P A, September 22, 1998: US05811447 (221 worldwide citation)

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a ce ...


4
David J Grainger, James C Metcalfe, Lawrence L Kunz, Robert W Schroff, Peter L Weissberg: Prevention and treatment of cardiovascular pathologies. NeoRx Corporation, Schwegman Lundberg Woessner & Kluth P A, June 23, 1998: US05770609 (99 worldwide citation)

A method for treating or preventing cardiovascular pathologies by administering a compound of the formula (I): ##STR1## wherein Z is C.dbd.O or a covalent bond; Y is H or O(C.sub.1 -C.sub.4)alkyl, R.sup.1 and R.sup.2 are individually (C.sub.1 -C.sub.4)alkyl or together with N are a saturated heteroc ...


5
David J Grainger, James C Metcalfe, Peter L Weissberg: Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells. NeoRx Corporation, Schwegman Lundberg Woessner & Kluth P A, August 13, 1996: US05545569 (50 worldwide citation)

TGF-beta activators and TGF-beta production stimulators are employed to maintain or increase vessel lumen diameter in a diseased or injured vessel of a mammal. Conditions such as restenosis following angioplasty, vascular bypass grafts, transplanted organs, atherosclerosis or hypertension are charac ...


6
David J Grainger, James C Metcalfe, Peter L Weissberg: Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells. NeoRx Corporation, Schwegman Lundberg & Woessner, December 5, 1995: US05472985 (39 worldwide citation)

TGF-beta activators and TGF-beta production stimulators are employed to prevent or treat conditions characterized by inappropriate proliferation of smooth muscle cells, such as the prevention or reduction of restenosis following angioplasty or other vascular trauma. Such TGF-beta activators and prod ...


7
David J Grainger, James C Metcalfe, Peter L Weissberg: Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells. NeoRx Corporation, Schwegman Lundberg Woessner & Kluth P A, February 4, 1997: US05599844 (37 worldwide citation)

TGF-beta activators and TGF-beta production stimulators are employed to prevent or treat conditions characterized by inappropriate proliferation of smooth muscle cells, such as the prevention or reduction of restenosis following angioplasty or other vascular trauma. Such TGF-beta activators and prod ...


8
David J Grainger, James C Metcalfe, Peter L Weissberg: Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells. NeoRx Corporation, Schwegman Lundberg Woessner & Kluth P A, August 31, 1999: US05945456 (29 worldwide citation)

TGF-beta activators and TGF-beta production stimulators are employed to prevent or treat conditions characterized by inappropriate proliferation of smooth muscle cells, such as the prevention or reduction of restenosis following angioplasty or other vascular trauma. Such TGF-beta activators and prod ...


9

10
David J Grainger, James C Metcalfe, Peter L Weissberg: Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells. NeoRx Corporation, Schwegman Lundberg Woessner & Kluth P A, June 30, 1998: US05773479 (27 worldwide citation)

TGF-beta activators and TGF-beta production stimulators are employed to prevent or treat conditions characterized by inappropriate proliferation of smooth muscle cells, such as the prevention or reduction of restenosis following angioplasty or other vascular trauma. Such TGF-beta activators and prod ...